Yidu Tech (02158.HK) launches "Yidu Smart Evidence," a nephrology-specific evidence-based decision-making tool, broadening the value chain of specialty evidence-based medicine.

Yidu Tech's (02158.HK) clinical evidence-based AI agent "Yidu ZhiXun" has partnered with the nephrology professional platform "JianShen ZhiKu" to officially launch a nephrology-specific evidence-based decision-making tool, according to Zhitong Finance APP. This marks another important practice by Yidu ZhiXun in deepening its presence in high-value specialties following the oncology field Yidu ZhiXun's specialty-focused layout is accelerating. After the tool's launch, it can provide nephrologists with clinical evidence-based support featuring second-level response and traceable evidence sources, and will also feed back into new drug R&D and real-world research in the nephrology field through the accumulation of specialty disease knowledge.